Conventional DMARD options for patients with a suboptimal response to methotrexate

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Methotrexate (MTX) is one of the disease modifying antirheumatic drugs (DMARD) commonly used to treat rheumatoid arthritis (RA). However, MTX therapy alone rarely results in remission and frequently does not even produce 50% improvement. Therefore, over the course of their disease, many patients will require additional therapy to manage their clinical symptoms. A number of treatment options have proven effective for such patients, most of which entail the continuation of MTX therapy and the addition of other DMARD. Although the combination of MTX and hydroxychloroquine (HCQ) is the one most commonly used in the US, many clinicians (particularly in Europe) prefer the combination of MTX and sulfasalazine. In addition, excellent data now exist for the triple combination of MTX, HCQ, and sulfasalazine in patients who have had a suboptimal response to MTX, as well as in those with early or well established disease. Other combinations, including MTX + cyclosporine or leflunomide, have also been helpful in some patients. Most recently, the tumor necrosis factor blockers, etanercept and infliximab, have successfully been used to treat a number of patients resistant to MTX. The combination of MTX with DMARD or biological agents with different mechanisms of action greatly expands the treatment options for patients with RA.

Original languageEnglish (US)
Pages (from-to)21-26
Number of pages6
JournalJournal of Rheumatology
Volume28
Issue numberSUPPL. 62
StatePublished - Jan 1 2001

Fingerprint

Antirheumatic Agents
Methotrexate
Hydroxychloroquine
Sulfasalazine
leflunomide
Rheumatoid Arthritis
Therapeutics
Biological Factors
Cyclosporine
Tumor Necrosis Factor-alpha

Keywords

  • Combination therapy
  • Disease modifying antirheumatic drugs
  • Methotrexate
  • Rheumatoid arthritis
  • Suboptimal response

ASJC Scopus subject areas

  • Rheumatology
  • Immunology and Allergy
  • Immunology

Cite this

Conventional DMARD options for patients with a suboptimal response to methotrexate. / O'Dell, James Robert.

In: Journal of Rheumatology, Vol. 28, No. SUPPL. 62, 01.01.2001, p. 21-26.

Research output: Contribution to journalArticle

@article{b223989b05384fe9909859f2428d7e03,
title = "Conventional DMARD options for patients with a suboptimal response to methotrexate",
abstract = "Methotrexate (MTX) is one of the disease modifying antirheumatic drugs (DMARD) commonly used to treat rheumatoid arthritis (RA). However, MTX therapy alone rarely results in remission and frequently does not even produce 50{\%} improvement. Therefore, over the course of their disease, many patients will require additional therapy to manage their clinical symptoms. A number of treatment options have proven effective for such patients, most of which entail the continuation of MTX therapy and the addition of other DMARD. Although the combination of MTX and hydroxychloroquine (HCQ) is the one most commonly used in the US, many clinicians (particularly in Europe) prefer the combination of MTX and sulfasalazine. In addition, excellent data now exist for the triple combination of MTX, HCQ, and sulfasalazine in patients who have had a suboptimal response to MTX, as well as in those with early or well established disease. Other combinations, including MTX + cyclosporine or leflunomide, have also been helpful in some patients. Most recently, the tumor necrosis factor blockers, etanercept and infliximab, have successfully been used to treat a number of patients resistant to MTX. The combination of MTX with DMARD or biological agents with different mechanisms of action greatly expands the treatment options for patients with RA.",
keywords = "Combination therapy, Disease modifying antirheumatic drugs, Methotrexate, Rheumatoid arthritis, Suboptimal response",
author = "O'Dell, {James Robert}",
year = "2001",
month = "1",
day = "1",
language = "English (US)",
volume = "28",
pages = "21--26",
journal = "Journal of Rheumatology",
issn = "0315-162X",
publisher = "Journal of Rheumatology",
number = "SUPPL. 62",

}

TY - JOUR

T1 - Conventional DMARD options for patients with a suboptimal response to methotrexate

AU - O'Dell, James Robert

PY - 2001/1/1

Y1 - 2001/1/1

N2 - Methotrexate (MTX) is one of the disease modifying antirheumatic drugs (DMARD) commonly used to treat rheumatoid arthritis (RA). However, MTX therapy alone rarely results in remission and frequently does not even produce 50% improvement. Therefore, over the course of their disease, many patients will require additional therapy to manage their clinical symptoms. A number of treatment options have proven effective for such patients, most of which entail the continuation of MTX therapy and the addition of other DMARD. Although the combination of MTX and hydroxychloroquine (HCQ) is the one most commonly used in the US, many clinicians (particularly in Europe) prefer the combination of MTX and sulfasalazine. In addition, excellent data now exist for the triple combination of MTX, HCQ, and sulfasalazine in patients who have had a suboptimal response to MTX, as well as in those with early or well established disease. Other combinations, including MTX + cyclosporine or leflunomide, have also been helpful in some patients. Most recently, the tumor necrosis factor blockers, etanercept and infliximab, have successfully been used to treat a number of patients resistant to MTX. The combination of MTX with DMARD or biological agents with different mechanisms of action greatly expands the treatment options for patients with RA.

AB - Methotrexate (MTX) is one of the disease modifying antirheumatic drugs (DMARD) commonly used to treat rheumatoid arthritis (RA). However, MTX therapy alone rarely results in remission and frequently does not even produce 50% improvement. Therefore, over the course of their disease, many patients will require additional therapy to manage their clinical symptoms. A number of treatment options have proven effective for such patients, most of which entail the continuation of MTX therapy and the addition of other DMARD. Although the combination of MTX and hydroxychloroquine (HCQ) is the one most commonly used in the US, many clinicians (particularly in Europe) prefer the combination of MTX and sulfasalazine. In addition, excellent data now exist for the triple combination of MTX, HCQ, and sulfasalazine in patients who have had a suboptimal response to MTX, as well as in those with early or well established disease. Other combinations, including MTX + cyclosporine or leflunomide, have also been helpful in some patients. Most recently, the tumor necrosis factor blockers, etanercept and infliximab, have successfully been used to treat a number of patients resistant to MTX. The combination of MTX with DMARD or biological agents with different mechanisms of action greatly expands the treatment options for patients with RA.

KW - Combination therapy

KW - Disease modifying antirheumatic drugs

KW - Methotrexate

KW - Rheumatoid arthritis

KW - Suboptimal response

UR - http://www.scopus.com/inward/record.url?scp=0035374819&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035374819&partnerID=8YFLogxK

M3 - Article

C2 - 11409154

AN - SCOPUS:0035374819

VL - 28

SP - 21

EP - 26

JO - Journal of Rheumatology

JF - Journal of Rheumatology

SN - 0315-162X

IS - SUPPL. 62

ER -